lunes, 3 de febrero de 2014 - 30 de Enero de 2014 - EEUU

Will Pfizer's Stop-Smoking Drug Hurt Big Tobacco?

Pfizer recently completed its first clinical test of varenicline, the company's smoking-cessation product, on patients who were unable or unwilling to abruptly quit smoking within a month. Results were good for Pfizer, and the drug met its primary and secondary endpoints. This is great news for Pfizer, but is it going to be bad news for Altria Group , Reynolds American , or Philip Morris International ?

No hay comentarios: